Clinical Study
Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
Table 3
Comparison of on-treatment factors between patients with and without sustained virological response.
| | Factors | SVR ( = 26) | Non-SVR ( = 7) | |
| | HCV-RNA level at week 1 (logIU/mL) | 1.3 | 2.4 | 0.399 | | HCV-RNA level at week 2 (logIU/mL) | 1.1 | 1.8 | 0.199 | | HCV-RNA level at week 4 (logIU/mL) | 0 | 1.2 | 0.039 | | RVR | 20 | 2 | 0.027 | | Reduction of HCV-RNA at week 1 (log) | 4.5 | 3.4 | 0.003 | | Reduction of HCV-RNA at week 2 (log) | 5.1 | 4.2 | 0.003 | | Reduction of HCV-RNA at week 4 (log) | 6.6 | 5.4 | 0.010 | | HCV core Ag level at week 1 (fmol/L) | 4.9 | 7.0 | 0.949 | | HCV core Ag level at week 2 (fmol/L) | 0.8 | 2.4 | 0.399 | | Reduction of HCV core Ag at week 1 | 4476.5 | 1517.5 | 0.399 | | Reduction of HCV core Ag at week 2 | 4477.4 | 1524.1 | 0.330 | | Telaprevir adherence (%) | 66.7 | 66.7 | 0.949 | | PEG-IFN adherence (%) | 68.4 | 68.5 | 0.846 | | Ribavirin adherence (%) | 70.9 | 75.0 | 0.682 |
|
|
Values are expressed as median. SVR, sustained virological response; HCV, hepatitis C virus; RVR, rapid virological response; Ag, antigen; PEG-IFN, pegylated interferon.
|
